Ultragenyx agrees to sell FDA priority review voucher for $210 million
Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher to receive $210 million, providing non-dilutive capital for its pipeline.
Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher to receive $210 million, providing non-dilutive capital for its pipeline.